Back to my company list

dreaMS

The AI engine Fit Assessment

Beta

MyHealios effectively employs remote monitoring technologies and focuses on the identification and validation of digital biomarkers to enhance clinical trials and patient care.

Blurb

Myhealios – Resilience coaching for caregivers Caregiving for a patient with a chronic condition can be difficult. MyHealios aims to address this unmet need by providing resilience coaching exclusively through TeleHealth. We work in alignment with established treatment plans and currently focusing on disease areas such as Schizophrenia and Multiple Sclerosis.

HQ Location

Flemington (United States)

Founded

2011

Employees

11 - 50

Total funding raised

$4.20M

Funding Status

Seed, August 30, 2022
Subspaces
  • Digital Biomarkers Development

Combining consumer devices' sensor data with AI, Dreams generates Digital Biomarkers to improve MS diagnosis and treatment monitoring.



dreaMS is a Software as Medical Device (CE-Mark) designed to assess neurological functions using novel Digital Biomarkers focused in the following domains: Movement, Balance, Dexterity and Vision



dreaMS is the product of a collaboration between Healios and RC2NB, a neuroscience research foundation connected to Universitätsspital Basel led by Professor L Kappos.